Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus fermentum GM-090
- Development stage
- Unknown
- Lead developer
- GenMont Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus fermentum GM-090 is a specific probiotic microbial strain isolated from the human gastrointestinal tract. Developed by GenMont Biotech, it is primarily investigated for its immunomodulatory properties in treating allergic diseases, particularly atopic dermatitis. The strain functions by stimulating the secretion of interferon-gamma (IFN-γ), which promotes a Th1-type immune response and inhibits the Th2-mediated allergic pathway, including the suppression of interleukin-4 (IL-4) and immunoglobulin E (IgE) synthesis. Clinical studies, including randomized controlled trials in children, have demonstrated its efficacy in reducing the severity of atopic dermatitis (measured by SCORAD scores) and improving quality of life, both as a monotherapy and in combination with other strains like *Lactobacillus paracasei*.
- Brand names
- LF GM-090
- Other names
- Lactobacillus fermentum GM-090L. fermentum GM-090
02
Targets
IL-4 (Interleukin 4)IFNG (Interferon gamma)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on lactobacillus fermentum GM-090.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus fermentum GM-090.